EMA. (2010) Guideline on the investigation of bioequivalence. European Medicines Agency, London, UK.

FDA. (2001) Guidance on statistical approaches to establishing bioequivalence. Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, MD.

FDA. (2015a) Scientific considerations in demonstrating biosimilarity to a reference product. Food and Drug Administration, Silver Spring, MD.

FDA. (2015b) Quality considerations in demonstrating biosimilarity to a reference protein product. Food and Drug Administration, Silver Spring, MD.

FDA. (2015c) Biosimilars: questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009. Food and Drug Administration, Silver Spring, MD.

Hsieh TC, Chow SC, Liu JP, et al. (2010) Statistical test for evaluation of biosimilarity of follow-on biologics. *Journal of Biopharmaceutical Statistics* **20**, 75–89.

Roger SD, Mikhail A. (2007) Biosimilars: opportunity or cause for concern? *Journal of Pharmaceutical Science* **10**, 405–410.

Schall R, Luus H. (1993) On population and individual bioequivalence. *Statistics in Medicine* **12**, 1109–1124.

Schellekens H. (2005) Follow-on biologics: challenges of the 'next generation'. *Nephrology, Dialysis, Transplantation* **20**, 31–36.

Shao J, Chow SC. (2002) Reproducibility probability in clinical trials. *Statistics in Medicine* **21**, 1727–1742.

Webber KO. (2007) Biosimilars: are we there yet? Presented at Biosimilars 2007, George Washington University, Washington, DC.

WHO. (2005) Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability (draft revision). World Health Organization, Geneva, Switzerland.